The role of SLAMF7 in multiple myeloma: impact on therapy

References

• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82(3):323–341.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21(3):529–534.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87(1):78–88.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(22):2806–2809.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Rovira M, Rosiñol L, Fernández-Avilés F, et al. Is there a curative potential of autologous stem cell transplantation in multiple myeloma? Long-term results from a single-centre series. Bone Marrow Transplant. 2009;42:S147. (abstract P592)
   Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood. 2015;126(23):391.
   Google Scholar
• Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752–5758. quiz 5982
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet Lond Engl. 2010;376(9758):2075–2085.
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9–19.
   PubMed Web of Science ®Google Scholar
• Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone Vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate Autologous Stem Cell Transplant (ASCT): results of the randomized Phase III Trial SWOG S0777. Blood. 2015;126(23):25.
   Google Scholar
• Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375–4382.
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396–406.
   PubMed Web of Science ®Google Scholar
• Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526–535.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–1337.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Cella M, Grierson HL, et al. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol Baltim Md 1950. 2001;167(10):5517–5521.
   Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(9):2775–2784.
   PubMed Web of Science ®Google Scholar
• Van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–2624.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol. 2011;29:665–705.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–2284.
   PubMed Web of Science ®Google Scholar
• Kumaresan PR, Lai WC, Chuang SS, et al. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Cruz-Munoz M-E, Dong Z, Shi X, et al. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10(3):297–305.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau J-L, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 1953–1959;30(16):2012.
   Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88(1):168–177.
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother CII. 2013;62(12):1841–1849.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127(23):2833–2840.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012).;120(3):552–559.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(16):1960–1965.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Granell M, Rocafiguera AO, et al. A phase II single-arm safety study of elotuzumab in combination with thalidomide and low dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. Hematologica. 2014;99(Suppl1):361–362.
   Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516–527.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib Study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129–138.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Sonneveld P. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. Expert Rev Hematol. 2015;8(4):481–491.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Facon T, Richardson P, et al. ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006) [abstract no. TPS8113]. J Clin Oncol. 2012;30(15Suppl).
   Google Scholar
• Usmani SZ, Hoering A, Sexton R, et al. SWOG 1211: a randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM) [abstract no. TPS8624]. J Clin Oncol. 2014;32(15Suppl 1).
   Google Scholar
• Neyer L, Ding H, Chen D, et al. Effect of elotuzumab on circulating lymphocytes, chemokines, and cytokines in multiple myeloma patients. Blood. 2010;116(21):4070.
   Google Scholar
• Dimopoulos M, Lonial S, Casado LF, et al. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2015;15:e267–e268.
   Google Scholar
• Bristol-Myers Squibb Company. EmplicitiTM (elotuzumab) for injection, for intravenous use: US prescribing information; 2015. [Cited 2015 Dec 1]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf
   Google Scholar
• Axel A, McCudden CR, Xie H, et al. Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma [abstract]. Cancer Res. 2014;74(Suppl 19): 2563
   Web of Science ®Google Scholar
• van de Donk NWCJ, Kamps S, Mutis T, et al. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012;26(2):199–213.
   PubMed Web of Science ®Google Scholar
• Sondergeld P, van de Donk NWCJ, Richardson PG, et al. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol HO. 2015;13(9):599–609.
   PubMedGoogle Scholar
• Nijhof IS, Axel A, Casneuf T, et al. Expression levels of CD38 and complement inhibitory proteins CD55 and CD59 predict response to daratumumab in multipe myeloma [abstract]. Haematologica. 2015;100(Suppl1):175–176.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(19):3113–3120.
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132(5):584–593.
   PubMed Web of Science ®Google Scholar
• Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13(2):79–90.
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 2013;90(6):441–468.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;924058:2011.
   Google Scholar
• Richardson PG, Lonial S, Jakubowiak AJ, et al. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011;154(6):745–754.
   PubMed Web of Science ®Google Scholar
• Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol. 2012;196063:2012.
   Google Scholar
• Godfrey J, Benson DM. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 1666–1676;53(9):2012.
   Google Scholar
• Orlowski RZ, Gercheva L, Williams C, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015;90(1):42–49.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014;123(26):4136–4142.
   PubMed Web of Science ®Google Scholar
• Raje NS, Faber EA, Richardson PG, et al. Phase 1 study of tabalumab, a human anti-BAFF antibody and bortezomib in patients with previously-treated multiple myeloma. Blood. 2012;120(21):447.
   Google Scholar
• Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013;163(4):478–486.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P et al. Preliminary results of a Phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. 56th American Society of Hematology (ASH) Annual Meeting and Exposition; 2014 Dec 6–9; San Francisco, CA. (abstract 291).
   Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet Lond Engl. 2016;387(10027):1551–1560.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Maus MV, Hwang W-T, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040–1047.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–927.
   PubMed Web of Science ®Google Scholar
• Danhof S, Gogishvili T, Koch S et al. CAR-Engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets. 57th Congress of ASH; 2015 Dec 5–8; Orlando, FL. (Oral session 652)
   Google Scholar